Spinal Muscular Atrophy (SMA)MyokinesisNCT07321977
Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
A study testing Gait analysis via video capture in people with Spinal Muscular Atrophy (SMA) and Charcot-Marie-Tooth, run by Institut de Myologie, France at 1 site in France.
Trial summary
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth, Muscular Dystrophy
- What is being tested?
- Gait analysis via video capture
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 3 Mar 2026to 6 Jan 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- All volunteers
- Individuals under guardianship, curatorship, or legal protection
- Pregnant or breastfeeding women
- Non-ambulatory individuals
- Individuals with epilepsy
- Skin conditions preventing the placement of VICON motion sensors
Show all 17Show fewer
- Asymptomatic volunteers
- Unstable respiratory or cardiac problems
- Neurological, musculoskeletal, or psychiatric problems
- Volunteers with a neuromuscular disease
- Recent trauma or serious falls (≤ 6 months)
- Individuals who have fallen more than twice in the past year and at least once in the past three months
- Use of assistive devices such as rigid knee braces or walkers
- Unstable cardiomyopathy
- Individuals awaiting diagnosis
- Inability to comply with the protocol requirements
- Medical or social conditions that could interfere with the study, as determined by the coordinating investigator or co-investigators.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre d'Exploration et d'Évaluation Neuromusculaire
Paris
Romain FEIGEAN, PhD, +33 01 42 16 58 80, r.feigean@institut-myologie.org
About this study
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.
- Conditions
- Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth, Muscular Dystrophy, Myotonic Dystrophy
- Being tested
- Gait analysis via video capture
- Keywords
- gait analysis, neuromuscular, disease, markerless
- Medical subject headings
- Muscular Atrophy, Spinal, Charcot-Marie-Tooth Disease, Muscular Dystrophies, Myotonic Dystrophy, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gait analysis via video captureOther
Using motion analysis software integrated into a smartphone
| Study group | Role | What they receive |
|---|---|---|
| Volunteers with Neuromuscular disease or asymptomatic | Other | All participants have the same intervention. The intervention is to walk with shoes in a gait analysis room with VICON markers on the body. At the same time, the participant will be film by two smartphones to compare the kinematics and the spatio-temporal parameters between a marker-based and a markerless gait analysis. Receives: Other: Gait analysis via video capture |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vicon vs Myokinesis system correlation coefficient
Correlation coefficient between measurements from the two systems in both groups, for spatiotemporal parameters and joint range of motion in the sagittal plane at the hip, knee, and ankle
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2026
- Study start3 Mar 2026
- Primary completion6 Jul 2026 (estimated)
- Study completion6 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Spinal Muscular Atrophy (SMA)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut de Myologie, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07321977
- Sponsor's protocol ID
- Myokinesis
- Acronym
- Myokinesis
- Status last verified
- May 2026
- First submitted
- 15 Dec 2025
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No